Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 2
2017 2
2018 2
2020 3
2021 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. Filho OM, et al. Cancer Discov. 2021 Oct;11(10):2474-2487. doi: 10.1158/2159-8290.CD-20-1557. Epub 2021 May 3. Cancer Discov. 2021. PMID: 33941592 Free PMC article. Clinical Trial.
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
Li Z, Metzger Filho O, Viale G, dell'Orto P, Russo L, Goyette MA, Kamat A, Yardley DA, Gupta Abramson V, Arteaga CL, Spring LM, Chiotti K, Halsey C, Waks AG, King TA, Lester SC, Bellon JR, Winer EP, Spellman PT, Krop IE, Polyak K. Li Z, et al. J Clin Invest. 2024 Feb 1;134(7):e176454. doi: 10.1172/JCI176454. J Clin Invest. 2024. PMID: 38300710 Free PMC article. Clinical Trial.
Classifying the evolutionary and ecological features of neoplasms.
Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D. Maley CC, et al. Nat Rev Cancer. 2017 Oct;17(10):605-619. doi: 10.1038/nrc.2017.69. Epub 2017 Sep 15. Nat Rev Cancer. 2017. PMID: 28912577 Free PMC article. Review.
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.
Risom T, Langer EM, Chapman MP, Rantala J, Fields AJ, Boniface C, Alvarez MJ, Kendsersky ND, Pelz CR, Johnson-Camacho K, Dobrolecki LE, Chin K, Aswani AJ, Wang NJ, Califano A, Lewis MT, Tomlin CJ, Spellman PT, Adey A, Gray JW, Sears RC. Risom T, et al. Nat Commun. 2018 Sep 19;9(1):3815. doi: 10.1038/s41467-018-05729-w. Nat Commun. 2018. PMID: 30232459 Free PMC article.
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Janiszewska M, Stein S, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop IE, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K. Janiszewska M, et al. JCI Insight. 2021 Jun 8;6(11):e147617. doi: 10.1172/jci.insight.147617. JCI Insight. 2021. PMID: 33886505 Free PMC article.
14 results